Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Varkey Mathew

Cardiovascular Disease Huntingtown, MD Medical Doctor

NPI 1245211481 CMS profile 56085

3995 Old Town Rd, Suite 101, Huntingtown, MD 20639

Open in the dashboard

General payments

$6,153

278 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Varkey Mathew of Huntingtown, MD is reported in the CMS Open Payments database as having received $6,153 across 278 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 73rd percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,045 39
2024 General $1,095 37
2023 General $813 42
2022 General $768 42
2021 General $743 40
2020 General $751 29
2019 General $938 49

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Varkey Mathew
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Varkey Mathew were reported at $1,045. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Varkey Mathew Cardiovascular Disease median Middle half National median
2019 $938 $450 $127–$1,392 $163
2020 $751 $242 $77–$751 $114
2021 $743 $335 $101–$1,037 $132
2022 $768 $395 $121–$1,211 $149
2023 $813 $443 $136–$1,283 $160
2024 $1,095 $450 $136–$1,323 $164
2025 $1,045 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pfizer Inc. $643 29 payments
  2. Merck Sharp & Dohme Corporation $639 36 payments
  3. Amgen Inc. $529 23 payments
  4. E.R. Squibb & Sons, L.L.C. $507 24 payments
  5. Novartis Pharmaceuticals Corporation $441 31 payments
  6. Esperion Therapeutics, Inc. $415 20 payments
  7. Actelion Pharmaceuticals US, Inc. $374 12 payments
  8. Kiniksa Pharmaceuticals, Ltd. $297 15 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $284 9 payments
  10. Venclose Inc. $255 3 payments
  11. Other $1,770 76 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,113 274 payments
  2. Education $40 4 payments
Products named General payments · program years 2019–2025
  1. VERQUVO $735 41 payments
  2. Repatha $442 19 payments
  3. ELIQUIS Cardiovascular $423 20 payments
  4. NEXLETOL $415 20 payments
  5. VYNDAQEL $369 15 payments
  6. OPSUMIT $351 11 payments
  7. ENTRESTO $270 21 payments
  8. EVRSF $255 3 payments
  9. ELIQUIS Cardiovascular;Metabolic Disease $253 13 payments
  10. Rapiblyk $243 1 payment
  11. Other $3,744 169 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 64 drugs

Part D claims

4,751

Median for Cardiology: 2,533

Drug cost

$1,310,289

Median for Cardiology: $485,213

Branded share of claims

28.2%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 182 $312,971
Eliquis Apixaban Brand 225 $261,142
Trulicity Dulaglutide Brand 107 $191,448
Mounjaro Tirzepatide Brand 80 $145,672
Xarelto Rivaroxaban Brand 71 $102,824
Jardiance Empagliflozin Brand 71 $96,591
Entresto Sacubitril/Valsartan Brand 35 $49,786
Nexletol Bempedoic Acid Brand 34 $34,491
Repatha Sureclick Evolocumab Brand 15 $20,392
Farxiga Dapagliflozin Propanediol Brand 17 $17,280

The 10 drugs with the highest cost, of 64 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 54 billing codes

Paid by Medicare

$833,086

Of which drugs: $3,847

Medicare patients

881

Average age 75

Services billed

8,141

450 women, 431 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 75%
Diabetes 54%
Arthritis 53%
Chronic kidney disease 30%
Atrial fibrillation 27%
COPD 21%
Heart failure 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, aminophyllin, up to 250 mg J0280 Office 126 386 $2,541
Injection, dipyridamole, per 10 mg J1245 Office 89 407 $1,270

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Arcalyst
  • Kiniksa Pharmaceuticals International, plc $151
$151 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $141
$141 17 —
OPSUMIT
  • Actelion Pharmaceuticals US, Inc. $128
$128 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $123
$123 71 —
VERQUVO
  • Merck Sharp & Dohme Corporation $96
$96 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

278 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record